60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has signed an exclusive option agreement with the Florida State University Research Foundation (FSURF) to advance Castanospermine for several…
July 09, 2026
July 08, 2026
MAIA Biotechnology Reports 90.5% Disease Control Rate in Third-Line NSCLC from THIO-101 Part C Expansion Trial
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, reported positive initial efficacy data on July 8, 2026…
July 08, 2026
Vanda Pharmaceuticals Wins FDA Rare Pediatric Disease Status For Ultra-Rare Nerve Disorder Drug
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for VCA‑894A, an investigational antisense therapy aimed…
Clearmind Medicine Inc. (Nasdaq: CMND) is taking a meaningful step toward turning its lead compound MEAI into a nasal spray treatment for alcohol use disorder…
Seer, Inc. (NASDAQ: SEER), a pioneer in proteomics, filed an investor presentation with the SEC on July 6, 2026 in connection with its Annual Meeting…
Vera Therapeutics, Inc. (NASDAQ: VERA), a biotechnology company focused on serious immunological diseases, saw shares rise 6% on July 6, 2026 as investors positioned ahead…
Allurion Technologies Inc. (ticker: ALUR) is ripping higher again today, with the stock up about 36% to 4.00 from a prior close of 2.94. Shares…
July 02, 2026
Artiva’s Off-the-Shelf Answer to Autoimmune CAR-T
The excitement in autoimmune disease right now runs through cell therapy. Researchers have shown that clearing a patient’s B cells can drive long remissions in…
July 01, 2026
Conexeu Sciences Opens Vancouver R&D Hub
Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility inside adMare BioInnovations’ M4 Innovation Centre in Vancouver, Canada, marking a key step…
Caris Life Sciences (NASDAQ: CAI), a next-generation AI TechBio company and precision medicine pioneer, announced the commercial launch of Caris Detect™ on July 1, 2026,…
June 30, 2026
FDA Grants Monopar Therapeutics Rare Pediatric Disease Designation for Wilson Disease Treatment
Monopar Therapeutics Inc. (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, secured Rare Pediatric Disease designation from the FDA for ALXN1840 in the treatment of Wilson disease…
June 30, 2026
Design Therapeutics Begins Patient Dosing of DT-818 in Phase 1 Trial for Myotonic Dystrophy
Design Therapeutics, Inc. (NASDAQ: DSGN), a clinical-stage biotechnology company, announced the initiation of patient dosing in its Phase 1 multiple-ascending dose trial of DT-818 on…